$149.60+0.50%Close 17 Nov 2026 · Market value $16.67B
About Revvity
Revvity is a health science company headquartered in Waltham, Massachusetts, with approximately 11,000 employees as of December 28, 2025. It provides instruments, reagents, assay platforms, software and services for life sciences research and drug discovery, serving pharmaceutical, biotech, contract research, academic and government customers. Its Diagnostics business offers screening and testing products, including prenatal, newborn, genomic and immunodiagnostic tests, sold to hospitals, medical labs, clinicians and research professionals. The company markets its products and services in more than 160 countries, using its own sales forces in approximately 40 countries and distributors elsewhere.
A summary of the business section of the company's latest annual report, filed 24 Feb 2026.
Company facts
| Ticker | RVTY · NYSE |
|---|
| Sector | Instruments |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 28 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 31791 |
|---|
| Latest annual report | 10-K, filed 24 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Prahlad R. Singh, PhD | Please See Remarks · Director | 416K · < 1% | Gift, 13 Aug 2026 |
|---|
| Joel S. Goldberg | Please See Remarks | 169K · < 1% | Gift, 14 Aug 2026 |
|---|
| Alexis P. Michas | Director | 78.6K · < 1% | Gift, 25 Aug 2026 |
|---|
| Maxwell Krakowiak | Please See Remarks | 68.0K · < 1% | Sale under a 10b5-1 plan, 21 Sep 2026 |
|---|
| Miriame Victor | Please See Remarks | 54.0K · < 1% | Option exercise, 24 Feb 2026 |
|---|
| Tajinder S. Vohra | Please See Remarks | 52.0K · < 1% | Sale under a 10b5-1 plan, 16 Sep 2026 |
|---|
| Peter Barrett | Director | 26.0K · < 1% | Grant or award, 7 May 2026 |
|---|
| Frank Witney, PhD | Director | 21.1K · < 1% | Grant or award, 7 May 2026 |
|---|
| Samuel R. Chapin | Director | 20.4K · < 1% | Grant or award, 7 May 2026 |
|---|
| Pascale Witz | Director | 13.7K · < 1% | Grant or award, 7 May 2026 |
|---|
| Michel Vounatsos | Director | 11.7K · < 1% | Grant or award, 7 May 2026 |
|---|
| Michael A. Klobuchar | Director | 5.1K · < 1% | Grant or award, 7 May 2026 |
|---|
| Sophie V. Vandebroek | Director | 5.1K · < 1% | Grant or award, 7 May 2026 |
|---|
| Michelle McMurry-Heath, MD/PhD | Director | 4.8K · < 1% | Grant or award, 7 May 2026 |
|---|
| Gonzales Anita | VP and CAO | — | Sale under a 10b5-1 plan, 1 Oct 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
RVTY in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.